- Before
- Owns 214 supplier sites in 31 countries and hears about a warning letter days late — then waits days more to learn which products it reaches.
- Now
- Starts the day on what changed overnight, sees the lit path and the sales on it, and signs a cited response.
One import alert, from FDA's posting to a signed response
Northwind Bio watches 214 supplier sites in 31 countries. On 7 October at 06:12, two new FDA items reach the signal tape: warning letter 320-26-41 and an Import Alert 66-40 entry for Hanvar Fine Chemicals in Vapi, India. Here is what happens next, screen by screen, in the working solution.
- 0106:12
The dependency graph, with every signal pinned on its site
Omar Haddad · Director, supply riskOmar's home is the graph: tier-2 suppliers, tier-1 supplier sites, critical materials and products with their annual sales. Single-source paths are drawn thick, second approved sources dashed — $11.3B of sales sit on single-source paths. Signals already read are tags on their sites: Typhoon 58 km on Kestrel Taizhou, CCC+ on Lumen Glass, Duty 25% on Shenlan Biochem, Port +6 d on Corlis Penang. Two new FDA items wait on the signal tape.
“Reading 96 feeds every 15 minutes · 214 supplier sites in 31 countries.”
- 02One click
The node turns red and the path lights to $1.2B
Signal reader · Site matcherThe signal reader takes the event, firm, FEI, address and dates from warning letter 320-26-41 and the Import Alert 66-40 entry. The site matcher lands them on Hanvar Vapi Unit II — FEI 3009817742 and Plot 214/2, GIDC Phase I. The thick path lights through talmirex sodium to Talmirex 20 mg tablets ($0.7B US) and Talmirex 40 mg tablets ($0.5B US).
“Vapi Unit II is the only US source of talmirex sodium · $1.2B of US sales on the path.”
- 03Same group, other unit
A near miss, logged with its reason
Site matcherHanvar also runs Vapi Unit IV, which makes talmirex hydrochloride for Talmirex oral solution. Neither the letter nor the alert names it: different FEI (3011094418), different address (Plot 88, Phase III). It is logged on the site with no alert and stays on watch because it shares the group quality unit. Of 41 signals read in 24 hours, 9 matched our sites, 1 was a near miss and 31 were set aside, each with the reason.
The site matcher never matches on a group name alone — it names the unit.
- 0406:14
A-1042 tops the risk register
Alert writerThe alert writer raises A-1042, FDA warning letter and import alert, on Hanvar Vapi Unit II: score 91, Talmirex 20 mg and 40 mg tablets, $1.2B a year, 23.3 weeks of cover, owner Omar Haddad. It sits above the Lumen Glass credit downgrade, Typhoon Haleka near Kestrel Taizhou and three other open alerts.
- 05Assess impact
Each step in view, with what it found
Seven agentsThe dependency mapper traces Vapi Unit II to talmirex sodium and to both tablet strengths, US and EU. The impact and cover calculator reads 412 kg on hand, 96 kg held at the port, 29 kg a week and 9.1 weeks of finished goods. The alternate source finder finds Meridian Química in Tarragona, approved for the EU, with 180 kg by 30 November. The regulatory impact checker finds the US filing names Unit II only.
“US filing names Unit II only · a new site needs a prior approval supplement · cover under 26 weeks: shortage notification assessment.”
- 06Assessed
23.3 weeks of US cover — and what is not affected
Impact and cover calculatorCover is the API on hand at Raleigh — 412 kg, 388 released and 24 in test, at 29 kg a week — plus 9.1 weeks of finished goods: 23.3 weeks for the 20 mg, 26.8 weeks for the 40 mg. The EU is supplied from Tarragona, and the oral solution is not affected. Every number cites its source row, and the warning letter opens beside it with the passages highlighted.
The 96 kg held at the port is not counted as cover until FDA releases it.
- 07The options
Three responses, each with its time to recover
Alternate source finder · Regulatory impact checkerA: bring Tarragona into the US filing — a prior approval supplement now and a 180 kg order, first US lot release about week 22, inside the 23.3 weeks. B: ask FDA to exclude talmirex sodium from the alert with independent batch testing — outcome uncertain, 9–20 weeks. C: wait for Hanvar — removal from Import Alert 66-40 typically takes a year or more after re-inspection. Option A is suggested, with six tasks and owners.
The regulatory impact checker advises only — regulatory decides, and no agent files or notifies a regulator.
- 08The letter
A supplier letter that cites the agreement
Alert writer · Sam PatelThe alert writer drafts the letter to Rakesh Varma, Hanvar's managing director, for Sam Patel to send. It cites clause 9.3 — written notice of any warning letter or import alert within five business days, not yet received — and asks by 14 October for Hanvar's FDA response and corrective action plan, the status of the 96 kg held at the port and, under clause 14.2, the technical information to qualify a second source.
Agents draft supplier messages; people send them.
- 09Sign
He signs option A, with his reason
Omar Haddad · Director, supply riskOmar approves “Bring Tarragona into the US filing” for A-1042, with the reason prefilled in the sign dialog: “Cover is 23.3 weeks; Tarragona recovers US supply in about 22 weeks if we file this month. Exclusion request kept as a fallback.” He signs with his password; six tasks will go to their owners.
Meaning of signature: “I approve this response plan.” Name, date and time are recorded in the audit trail.
- 10Mitigating
Six tasks, six owners
The response teamA-1042 moves to Mitigating. Dana Okafor orders 180 kg from Tarragona by 9 October; Priya Raman files the prior approval supplement by 23 October and decides on a shortage notification by 14 October; Dr. Maya Chen confirms Tarragona for US supply in the quality system by 16 October; Lena Ortiz, the supply planner, holds the 412 kg for US Talmirex and allocates the 40 mg strength; Sam Patel asks Hanvar for its response and CAPA plan.
“Signed · A-1042 is now Mitigating · 6 tasks sent to their owners.”